Trudi Fondren
Trudi Fondren worked at Mass General Hospital for almost 40 years. During her time here, she worked as a lab and research technologist and was part of the Friends of the Mass General Cancer Center.
Contact Information
Mass General Cancer Center
55 Fruit Street
Boston,
MA
02114
Phone: 877-726-5130
Support Sarcoma Research
Help our team at the Center for Sarcoma and Connective Tissue Oncology improve outcomes while providing extraordinary care to patients with sarcoma and musculoskeletal tumors. Make a gift.
Our multidisciplinary team of cancer specialists provides comprehensive, individually tailored treatment for children and adults with bone cancers including osteosarcoma, chondrosarcoma, and the Ewing Family of Tumors (EFTs). It is important to seek treatment from experts with extensive experience in diagnosing and managing these rare cancers. Our program is one of the oldest, largest and most experienced sarcoma treatment programs in the world.
In addition to those mentioned above, we also treat these types of bone sarcomas:
At the Center for Sarcoma and Connective Tissue Oncology, we offer cutting edge care and innovative surgical, medical oncology, and radiation oncology treatments designed to eradicate the tumor, prevent local recurrence, improve survival and optimize limb function.
Our surgeons are internationally respected and are active participants in a national clinical trials network that allows us to bring new treatments to our patients as quickly as possible. We offer a unique treatment resource for primary tumors of the spine, and we are one of only a few centers in the United States that provide proton beam therapy in addition to state-of-the-art surgery and targeted chemotherapy.
Our musculoskeletal pathologists sub-specialize in diagnosing and staging skeletal system tumors. They use a variety of biomarkers and molecular techniques to categorize each tumor, which helps determine the most effective course of treatment.
Our pathologists work very closely with our radiologists, orthopedic oncology surgeons, spine surgeons and surgical oncologists to develop the best therapeutic strategies for each patient’s cancer. During surgery, our pathologists analyze tumor samples to help ensure that the surgeons completely remove the entire tumor with negative margins (no surrounding cancer).
Advanced imaging technologies provide diagnostic and staging information and include:
Our team approach ensures that every patient benefits from an individualized, coordinated and compassionate treatment plan, with care provided by leading experts from many specialties. We consider all individuals involved in the patient's care to be part of this team, including:
Mass General Cancer Center's Adolescent and Young Adult (AYA) Cancer Program provides specialized resources and support for our AYA patients. Patients can access supportive care resources including social work, psychology, psychiatry, sexual health and fertility, lifestyle medicine, integrative therapies, and parenting guidance. Dedicated AYA clinicians and program manager are available to connect patients to these resources and answer any questions.
We offer a full range of chemotherapeutic agents, including angiogenesis inhibitors and molecularly targeted agents. Through our clinical trials program, we are able to offer many new, investigational medications for appropriately selected patients. Research conducted at our Cancer Center and elsewhere is leading to better understanding of the genetic basis of bone cancers and pointing the way to new treatment strategies. Additional research is focused on the problem of reverse drug resistance in sarcoma.
Our surgeons are leaders in bone tumor resection and complex reconstructions, using a variety of implants and transplants to optimize limb function. Today, 90 to 95 percent of our bone cancer patients can be safely treated with limb-sparing techniques.
Our orthopaedic oncology surgeons work with their colleagues from the Mass General Spine Service and with other subspecialty surgeons, depending on the location of the tumor. They are internationally known for their expertise in complex spinal operations, including “en bloc” resections – wide excisions of tumor in difficult anatomic locations, and in innovative reconstruction procedures.
Our radiation oncologists offer a range of therapies designed to shrink or destroy tumors while protecting normal tissue. Advanced technologies include:
Learn more about radiation therapy for sarcomas.
Research conducted at Massachusetts General Hospital Cancer Center and other cancer centers is leading to better understanding of the genetic basis of soft tissue sarcomas. Our investigators are focused on identifying genetic mutations associated with sarcoma and biologic markers that predict tumor behavior. Findings will help shape new treatment strategies. Our laboratory researchers are also developing novel strategies to reverse drug resistance in sarcoma, supported in part by the Cancer Center’s world-renowned archive of sarcoma tissue and associated clinical information. Results are being used to design new clinical trials.
The Sarcoma/Oncology Computational Biology Laboratory conducts cancer genomic/bioinformatics studies in order to detect molecular patterns relevant to tumor outcome and response to conventional or novel treatments.
Clinical trials are research studies of new drugs, new combinations of drugs or already approved drugs being studied to treat patients in new/different ways. They may include new drug doses or new ways (schedules) to give the drugs. Clinical trials are run under strict guidelines. Their purpose is to help find out whether new cancer treatments are safe and effective or better than the standard (current) treatment. At Massachusetts General Hospital Cancer Center, there are several clinical trials open for the treatment of sarcomas that use the latest cancer treatments.
Santiago Lozano-Calderon, MD, PhD
The Center for Sarcoma and Connective Tissue Oncology is one of the largest and most experienced sarcoma and chordoma treatment groups in the country. Our team specializes in the diagnosis and treatment of bone and soft tissue tumors, and provides the latest and most innovative treatments matched with compassionate care. Learn more from our team in this video.
This program addresses the unique needs of patients with cancer ages 15-39.
This program helps patients regain physical abilities and maintain independence.
We offer a variety of education and support resources to help you and your family.
Personalized, team-oriented care for patients whose cancer has spread to their bones.
A checklist of items to bring with you for your first visit and helpful information.
We offer a wide range of integrative therapies, workshops and support groups.
See our Wellness and Support Program calendar.
View select publications from the Center for Sarcoma and Connective Tissue Oncology.
Mass General has the only proton therapy site in all of New England, with two proton therapy centers.
This helped lead to new knowledge and breakthrough therapies.
Trudi Fondren worked at Mass General Hospital for almost 40 years. During her time here, she worked as a lab and research technologist and was part of the Friends of the Mass General Cancer Center.
Anthony has been a patient at the Cancer Center for over 17 years. Anthony’s strong commitment to his wife, Nina, and love for his family has kept him going.
Contact us to make an appointment or if you have any questions.